4:18 PM
 | 
Jan 11, 2013
 |  BC Extra  |  Clinical News

Mesoblast gains on Phase II spine fusion data

Mesoblast Ltd. (ASX:MSB; Pink:MBLTY) gained A$0.50 (10%) to A$5.74 on Friday after reporting data from an open-label, U.S. Phase II trial of the company's NeoFuse mesenchymal precursor...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >